Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
A systematic review examining studies on BPC-157 and musculoskeletal healing found that the vast majority were preclinical (primarily conducted in rats), with very limited clinical data in humans
Investigators have examined its interactions with the hypothalamic-pituitary-adrenal (HPA) axis, stress response systems, and neuroendocrine signaling, as well as its apparent ability to cross the blood-brain barrier under certain experimental conditions
Exp Neurol 2015;263:177-89
doi:10.1371/journal.pone.0033944 Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, Hillegass WB, Rocha-Singh K, Moon TE, Whitehouse MJ et al (2002) Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial
It interacts with the dopaminergic system and appears to have neuroprotective properties
Understanding these differences provides an important foundation for comparing how peptides and steroids work, their potential benefits, associated risks, expected timelines for results, and overall treatment costs
